We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

News   Aug 10, 2009

 
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
 
 
 

RELATED ARTICLES

Metabolic Dysfunction Could Be a Potential Therapy for Alzheimer’s Disease

News

A team of researchers led by Yale-NUS College has found evidence that metabolic dysfunction is a primary cause of Alzheimer's disease.

READ MORE

It Is Possible to Extend Life Without Any Genetic Modification, Study Suggests

News

Given the relationship between telomeres and ageing - telomeres shorten throughout life, so older organisms have shorter telomeres -, scientists launched a study generating mice in which 100% of their cells had hyper-long telomeres.

READ MORE

A New Way of Creating the Building Blocks of Drugs

News

A team have discovered how to synthesize the most common molecule arrangement in medicine, a scientific discovery that could change the way a number of drugs are produced.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE